CellPro cuts expenditure to cope with litigation
This article was originally published in Clinica
CellPro has carried out an internal reorganisation, including an 11% cut in its workforce, to reduce expenditure as the company defends both a patent litigation battle and a class action lawsuit by investors. The company hopes to reduce its monthly cash burn by around $300,000-500,000 from the present figure of nearly $2 million.
You may also be interested in...
Indoco’s domestic performance picks up pace as the Indian pharma market sees a “bounce back” after a long COVID-induced slump. The Indian company continues to perform well internationally and grow overall.
The MHRA has been working all hours to ensure the standalone medtech UKCA mark works operationally and procedurally in the UK as of 1 January 2021.
Development Partners International, CDC Group and the European Bank for Reconstruction and Development have collaborated to create a “first of its kind, pan-African” generics platform built on the acquisition and combination of Egypt’s Adwia Pharmaceuticals and India’s Celon Laboratories. An initial $250m investment is to be followed by up to $500m in further funding.